301 related articles for article (PubMed ID: 27374454)
1. Patterns of Locoregional Relapses in Patients with Contemporarily Staged Stage III-N2 NSCLC Treated with Induction Chemotherapy and Resection: Implications for Postoperative Radiotherapy Target Volumes.
Billiet C; De Ruysscher D; Peeters S; Decaluwé H; Vansteenkiste J; Dooms C; Deroose CM; De Leyn P; Hendrikx M; Bulens P; Le Péchoux C; Mebis J
J Thorac Oncol; 2016 Sep; 11(9):1538-49. PubMed ID: 27374454
[TBL] [Abstract][Full Text] [Related]
2. Outcome after PORT in ypN2 or R1/R2 versus no PORT in ypN0 Stage III-N2 NSCLC after Induction Chemotherapy and Resection.
Billiet C; Peeters S; Decaluwé H; Vansteenkiste J; Dooms C; Deroose CM; Hendrikx M; De Leyn P; Bulens P; Karim R; Le Péchoux C; Mebis J; De Ruysscher D
J Thorac Oncol; 2016 Nov; 11(11):1940-1953. PubMed ID: 27393474
[TBL] [Abstract][Full Text] [Related]
3. [Factors influencing survival and recurrence and potential significance of postoperative radiotherapy and adjuvant chemotherapy for stage ⅢA-N2 non-small cell lung cancer].
Han W; Song YZ; He M; Li J; Zhang R; Qiao XY
Zhonghua Zhong Liu Za Zhi; 2016 Nov; 38(11):861-867. PubMed ID: 27998447
[No Abstract] [Full Text] [Related]
4. Patterns of local-regional failure in completely resected stage IIIA(N2) non-small cell lung cancer cases: implications for postoperative radiation therapy clinical target volume design.
Feng W; Fu XL; Cai XW; Yang HJ; Wu KL; Fan M; Xiang JQ; Zhang YW; Chen HQ
Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):1100-7. PubMed ID: 24529715
[TBL] [Abstract][Full Text] [Related]
5. The impact of extent and location of mediastinal lymph node involvement on survival in Stage III non-small cell lung cancer patients treated with definitive radiotherapy.
Fernandes AT; Mitra N; Xanthopoulos E; Evans T; Stevenson J; Langer C; Kucharczuk JC; Lin L; Rengan R
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):340-7. PubMed ID: 22104359
[TBL] [Abstract][Full Text] [Related]
6. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
Kumar P; Herndon J; Langer M; Kohman LJ; Elias AD; Kass FC; Eaton WL; Seagren SL; Green MR; Sugarbaker DJ
Cancer; 1996 Jun; 77(11):2393-9. PubMed ID: 8635112
[TBL] [Abstract][Full Text] [Related]
7. Postoperative intensity-modulated radiation therapy reduces local recurrence and improves overall survival in III-N2 non-small-cell lung cancer: A single-center, retrospective study.
Wei W; Zhou J; Zhang Q; Liao DH; Liu QD; Zhong BL; Liang ZB; Zhang YC; Jiang R; Liu GY; Xu CY; Li Zhou H; Zhu SY; Yang N; Jiang W; Liu ZG
Cancer Med; 2020 Apr; 9(8):2820-2832. PubMed ID: 32100444
[TBL] [Abstract][Full Text] [Related]
8. Postoperative radiotherapy for patients with completely resected pathological stage IIIA-N2 non-small cell lung cancer: focusing on an effect of the number of mediastinal lymph node stations involved.
Matsuguma H; Nakahara R; Ishikawa Y; Suzuki H; Inoue K; Katano S; Yokoi K
Interact Cardiovasc Thorac Surg; 2008 Aug; 7(4):573-7. PubMed ID: 18413349
[TBL] [Abstract][Full Text] [Related]
9. Postoperative Radiotherapy for Surgically Resected ypN2 Non-Small Cell Lung Cancer.
Brandt WS; Yan W; Leeman JE; Tan KS; Park BJ; Adusumilli PS; Bott MJ; Molena D; Isbell J; Chaft J; Rimner A; Jones DR
Ann Thorac Surg; 2018 Sep; 106(3):848-855. PubMed ID: 29807005
[TBL] [Abstract][Full Text] [Related]
10. Role of postoperative radiotherapy after curative resection and adjuvant chemotherapy for patients with pathological stage N2 non-small-cell lung cancer: a propensity score matching analysis.
Kim BH; Kim HJ; Wu HG; Kang CH; Kim YT; Lee SH; Kim DW
Clin Lung Cancer; 2014 Sep; 15(5):356-64. PubMed ID: 24996882
[TBL] [Abstract][Full Text] [Related]
11. Postoperative radiotherapy for patients with completely resected pathologic n2 non-small-cell lung cancer: a retrospective analysis.
Mantovani C; Levra NG; Filippi AR; Novello S; Buffoni L; Ragona R; Ricardi U
Clin Lung Cancer; 2013 Mar; 14(2):194-9. PubMed ID: 22885347
[TBL] [Abstract][Full Text] [Related]
12. Postoperative radiotherapy is effective in improving survival of patients with stage pIII-N2 non-small-cell lung Cancer after pneumonectomy.
Wang W; Men Y; Wang J; Zhou Z; Chen D; Xiao Z; Feng Q; Lv J; Liang J; Bi N; Gao S; Wang L; Hui Z
BMC Cancer; 2019 May; 19(1):478. PubMed ID: 31113432
[TBL] [Abstract][Full Text] [Related]
13. Postinduction positron emission tomography assessment of N2 nodes is not associated with ypN2 disease or overall survival in stage IIIA non-small cell lung cancer.
Ripley RT; Suzuki K; Tan KS; Adusumilli PS; Huang J; Park BJ; Downey RJ; Rizk NP; Rusch VW; Bains M; Jones DR
J Thorac Cardiovasc Surg; 2016 Apr; 151(4):969-77, 979.e1-3. PubMed ID: 26614420
[TBL] [Abstract][Full Text] [Related]
14. The lymph node status and histologic subtypes influenced the effect of postoperative radiotherapy on patients with N2 positive IIIA non-small cell lung cancer.
Yuan C; Tao X; Zheng D; Pan Y; Ye T; Hu H; Xiang J; Zhang Y; Chen H; Sun Y
J Surg Oncol; 2019 Mar; 119(3):379-387. PubMed ID: 30536966
[TBL] [Abstract][Full Text] [Related]
15. Analysis of Patients Unable to Undergo Adjuvant Chemotherapy after Surgery in Stage IIIA/B Non-Small Cell Lung Cancer: Will They Benefit from Mediastinal Radiotherapy?
Graeter TP; Sebastian B; Bischof M; Kugler G; Fischer JR; Schneider T
Thorac Cardiovasc Surg; 2016 Sep; 64(6):501-6. PubMed ID: 26322832
[TBL] [Abstract][Full Text] [Related]
16. Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial.
Le Pechoux C; Pourel N; Barlesi F; Lerouge D; Antoni D; Lamezec B; Nestle U; Boisselier P; Dansin E; Paumier A; Peignaux K; Thillays F; Zalcman G; Madelaine J; Pichon E; Larrouy A; Lavole A; Argo-Leignel D; Derollez M; Faivre-Finn C; Hatton MQ; Riesterer O; Bouvier-Morel E; Dunant A; Edwards JG; Thomas PA; Mercier O; Bardet A
Lancet Oncol; 2022 Jan; 23(1):104-114. PubMed ID: 34919827
[TBL] [Abstract][Full Text] [Related]
17. Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival.
Decaluwé H; De Leyn P; Vansteenkiste J; Dooms C; Van Raemdonck D; Nafteux P; Coosemans W; Lerut T
Eur J Cardiothorac Surg; 2009 Sep; 36(3):433-9. PubMed ID: 19502079
[TBL] [Abstract][Full Text] [Related]
18. Results of induction chemotherapy followed by surgical resection in patients with stage IIIA (N2) non-small cell lung cancer: the importance of the nodal down-staging after chemotherapy.
Voltolini L; Luzzi L; Ghiribelli C; Paladini P; Di Bisceglie M; Gotti G
Eur J Cardiothorac Surg; 2001 Dec; 20(6):1106-12. PubMed ID: 11717012
[TBL] [Abstract][Full Text] [Related]
19. The role of consolidation therapy for stage III non-small cell lung cancer with persistent N2 disease after induction chemotherapy.
Amini A; Correa AM; Komaki R; Chang JY; Tsao AS; Roth JA; Swisher SG; Rice DC; Vaporciyan AA; Lin SH
Ann Thorac Surg; 2012 Sep; 94(3):914-20. PubMed ID: 22819472
[TBL] [Abstract][Full Text] [Related]
20. The emerging outcome of postoperative radiotherapy for stage IIIA(N2) non-small cell lung cancer patients: based on the three-dimensional conformal radiotherapy technique and institutional standard clinical target volume.
Feng W; Zhang Q; Fu XL; Cai XW; Zhu ZF; Yang HJ; Xiang JQ; Zhang YW; Chen HQ
BMC Cancer; 2015 May; 15():348. PubMed ID: 25934006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
